arrow
C

Catherine Diefenbach

new york university langone health
H指数:35
被引数:5,664

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma

纳武利尤单抗-AVD和 Brentuximab Vedotin-AVD在儿童和成人晚期霍奇金淋巴瘤中的真实世界结局

2026-09-290
PRE
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma

一项随机II期研究:皮下注射mosunetuzumab联合polatuzumab vedotin与利妥昔单抗联合polatuzumab vedotin治疗复发或难治性大B细胞淋巴瘤患者的比较研究

2026-07-280
OAAI
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma

伊匹木单抗、纳武利尤单抗和 Brentuximab Vedotin 治疗复发霍奇金淋巴瘤的随机二期研究

Blood
IF23.1
2026-04-011
PRE
Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers

纳武利尤单抗联合AVD方案作为经典霍奇金淋巴瘤患者的一线治疗方案:一项来自20家美国中心的真实世界分析

2026-03-310
OAAI
NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma

NKTR-255可增强CD19 CAR-T在复发/难治性大B细胞淋巴瘤患者中的完全缓解率。

2025-08-110
OAAI
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
2024-02-013
PRE
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
2023-12-135
OAAI
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
2023-12-1018
OAAI
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
2023-12-013
OAAI
A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas
2023-04-141
PRE
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma
2023-01-1110
OAAI